Johnson & Johnson launches 3 new stroke devices

Johnson & Johnson MedTech has officially launched three new devices, the Cereglide 42 and Cereglide 57 aspiration catheters and the Innerglide 7 deliver aid. The devices, the three latest additions to Johnson & Johnson MedTech’s aspiration-first stroke portfolio, were developed to help clinicians reach and remove distal clots associated with significant pain and swelling. If left untreated, these clots can lead to medical emergencies and even death.

“We designed this multi-axial system to address procedural challenges physicians face when treating stroke,” Christian Cuzick, worldwide president of Johnson & Johnson’s neurovascular division, said in a statement. “With this expanded portfolio, we’re simplifying decisions, enhancing consistency across device sizes, and reinforcing our commitment to helping improve patient outcomes.”

The Cereglide 42 and Cereglide 57 catheters

The Cereglide 42 and Cereglide 57 catheters were built with a proprietary technology that is both supportive and flexible, allowing users to target challenging thrombi. According to Johnson & Johnson MedTech, they include radiopaque tip markers that increase visibility during treatment and a hydrophilic coating that minimizes the risk of doing damage to the patient’s anatomy. 

“Accessing distal occlusions remains one of the biggest technical challenges we face, especially in smaller or more tortuous vessels,” Ameer E. Hassan, DO, a vascular specialist with the Neuroscience Institute at Valley Baptist Medical Center, said in the same statement. “In my experience, Cereglide 42 and 57 track reliably while maintaining strong proximal support, even over multiple passes. That balance of flexibility and control gives me greater confidence when performing aspiration-first thrombectomy in more complex anatomy.”